

Yasuhito Miyake,^a Asao
Hosoda,^b Eisaku Nomura^b and
Hisaji Taniguchi^{b*}^aJapan Science and Technology Corporation,
60 Ogura, Wakayama 649-6261, Japan, and
^bIndustrial Technology Center of Wakayama
Prefecture, 60 Ogura, Wakayama 649-6261,
JapanCorrespondence e-mail:
taniguti@wakayama-kg.go.jp


Key indicators

Single-crystal X-ray study
 $T = 193\text{ K}$
Mean $\sigma(\text{C}-\text{C}) = 0.003\text{ \AA}$
 R factor = 0.059
 wR factor = 0.120
Data-to-parameter ratio = 10.5For details of how these key indicators were
automatically derived from the article, see
<http://journals.iucr.org/e>.

Ethyl 3-(4-geranyloxy-3-methoxyphenyl)-2-propenoate

Received 9 August 2001
Accepted 16 October 2001
Online 20 October 2001The title compound, $\text{C}_{22}\text{H}_{30}\text{O}_4$, is known as a chemopreventive agent against colon tumor development. The molecular structure is nearly planar, showing a *trans* arrangement with respect to the $\text{C}=\text{C}$ bond of the phenylpropenoate moiety.

Comment

The title compound, (I), is known as a chemopreventive agent against colon tumor development (Tsuda *et al.*, 1999). It was prepared from ferulic acid, which was easily prepared in large quantities from the oily component of rice bran (Taniguchi *et al.*, 1996).The molecular structure of (I) is shown in Fig. 1, confirming the *trans* arrangement with respect to the $\text{C7}=\text{C8}$ double bond, similar to ferulic acid (Nethaji *et al.*, 1988). The orientations of the phenyl ring and the geranyl group are defined by the torsion angles in Table 1. The molecule is nearly planar. The molecules in the crystal lattice are in a conventional herring-bone-type arrangement (Fig. 2). No close contacts were found that indicated any relevant intermolecular interaction.

Experimental

To a solution of 1.0 g (4.5 mmol) of ethyl ferulate, ethyl ester of ferulic acid, 1.2 g (4.6 mmol) of triphenylphosphine and 0.69 g (4.5 mmol) of geraniol in 10 ml anhydrous tetrahydrofuran was added 0.93 g (4.6 mmol) diisopropyl azodicarboxylate. The mixture was stirred for 5 min at room temperature and the solvent then removed under reduced pressure. After the residue was extracted with 30 ml of hexane, the hexane was removed under reduced pressure. Recrystallization from methanol gave the pure title compound (I) (1.37 g, 85%). Crystals of (I) were obtained by slow evaporation of an ethanol solution at 277–279 K.

Crystal data

 $\text{C}_{22}\text{H}_{30}\text{O}_4$
 $M_r = 358.48$
Triclinic, $P\bar{1}$
 $a = 11.094(1)\text{ \AA}$
 $b = 11.943(1)\text{ \AA}$
 $c = 9.3399(9)\text{ \AA}$
 $\alpha = 110.864(5)^\circ$
 $\beta = 113.510(5)^\circ$
 $\gamma = 68.358(4)^\circ$
 $V = 1022.5(2)\text{ \AA}^3$ $Z = 2$
 $D_x = 1.164\text{ Mg m}^{-3}$
Cu $K\alpha$ radiation
Cell parameters from 2787
reflections
 $\theta = 4.1\text{--}67.5^\circ$
 $\mu = 0.63\text{ mm}^{-1}$
 $T = 193.2\text{ K}$
Prism, colorless
 $0.60 \times 0.58 \times 0.30\text{ mm}$




Figure 1
The molecular structure of (I) showing 50% probability displacement ellipsoids.

Data collection

Rigaku R-Axis-RAPID image-plate diffractometer
 ω scans
Absorption correction: multi-scan (Higashi, 1995)
 $T_{\min} = 0.587$, $T_{\max} = 0.828$
5896 measured reflections

3429 independent reflections
3094 reflections with $F^2 > 2.0\sigma(F^2)$
 $R_{\text{int}} = 0.028$
 $\theta_{\text{max}} = 68.2^\circ$
 $h = -13 \rightarrow 13$
 $k = -14 \rightarrow 14$
 $l = -11 \rightarrow 11$

Refinement

Refinement on F
 $R = 0.059$
 $wR = 0.121$
 $S = 1.65$
3429 reflections
326 parameters
H-atom parameters constrained

$w = 1/[\sigma^2(F_o) + 0.00403|F_o|^2]$
 $(\Delta/\sigma)_{\text{max}} < 0.001$
 $\Delta\rho_{\text{max}} = 0.51 \text{ e } \text{\AA}^{-3}$
 $\Delta\rho_{\text{min}} = -0.28 \text{ e } \text{\AA}^{-3}$
Extinction correction: Zachariasen (1967) type 2 Gaussian isotropic
Extinction coefficient: 0.39 (6)

Table 1

Selected torsion angles ($^\circ$).

O(1)–C(13)–C(14)–C(15)	180.0 (1)
O(3)–C(9)–O(4)–C(10)	–1.1 (3)
O(3)–C(9)–C(8)–C(7)	–176.8 (2)
O(4)–C(9)–C(8)–C(7)	3.2 (3)
C(1)–O(1)–C(13)–C(14)	–178.2 (1)
C(1)–C(2)–O(2)–C(12)	177.6 (2)
C(2)–C(1)–O(1)–C(13)	179.4 (1)
C(3)–C(2)–O(2)–C(12)	–3.6 (3)
C(3)–C(4)–C(7)–C(8)	174.6 (2)
C(4)–C(7)–C(8)–C(9)	178.4 (2)
C(5)–C(4)–C(7)–C(8)	–5.9 (3)
C(6)–C(1)–O(1)–C(13)	0.6 (2)
C(8)–C(9)–O(4)–C(10)	178.9 (1)
C(9)–O(4)–C(10)–C(11)	–177.5 (2)
C(13)–C(14)–C(15)–C(16)	178.3 (1)
C(13)–C(14)–C(15)–C(21)	–0.1 (3)
C(14)–C(15)–C(16)–C(17)	–2.3 (2)
C(15)–C(16)–C(17)–C(18)	–177.1 (1)
C(16)–C(17)–C(18)–C(19)	170.5 (2)
C(17)–C(16)–C(15)–C(21)	176.1 (1)
C(17)–C(18)–C(19)–C(20)	179.6 (2)
C(17)–C(18)–C(19)–C(22)	0.8 (3)

The measured fraction ($\theta_{\text{max}} = 68.2^\circ$) of 0.917 is relatively low, which may be ascribed to either a short exposure time of the image plate or the instrument having only one rotation axis, leaving some parts of reciprocal space inaccessible.

Data collection: *PROCESS-AUTO* (Rigaku, 1998); cell refinement: *PROCESS-AUTO*; data reduction: *TEXSAN* (Molecular Structure Corporation, 1999); program(s) used to solve structure:




Figure 2
Projection down the c axis of the unit cell of (I)

SHELXS97 (Sheldrick, 1997); program(s) used to refine structure: *TEXSAN*; software used to prepare material for publication: *TEXSAN*.

This study was performed through support from the Special Coordination Funds for Promoting Science and Technology (Leading Research Utilizing Potential of Regional Science and Technology) of the Ministry of Education, Culture, Sports, Science and Technology of the Japanese Government.

References

- Higashi, T. (1995). *ABSCOR*. Rigaku Corporation, Tokyo, Japan.
Molecular Structure Corporation (1999). *TEXSAN*. Version 1.10. MSC, 9009 New Trails Drive, The Woodlands, TX 77381–5209, USA.
Nethaji, M., Pattabhi, V. & Desiraju, G. R. (1988). *Acta Cryst.* **C44**, 275–277.
Rigaku (1998). *PROCESS-AUTO*. Rigaku Corporation, Tokyo, Japan.
Sheldrick, G. M. (1997). *SHELXS97*. University of Göttingen, Germany.
Taniguchi, H., Nomura, E., Tsuno, T., Minami, S., Kato, K., Hayashi, C. (1996). Japanese Patent No. 2 095 088; US Patent (1994). No. 5 288 902.
Tsuda, H., Park, C. B., Takasuka, N., Toriyama, H., Sekine, K., Moore, M. A., Nomura, E. & Taniguchi, H. (1999). *Anticancer Res.* **19**, 3779–3782.
Zachariasen, W. H. (1967). *Acta Cryst.* **23**, 558–564.